Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19699916 | 0.86 | ALDH1A1 (0.39) | ALDH1A1SLC2A1 | |
| SCHEMBL24515014 | 0.82 | SLC2A1 (0.32) | SLC2A1 | |
| SCHEMBL19733381 | 0.79 | ALDH1A1 (0.34) | ALDH1A1PIK3CDTRPM8 | |
| SCHEMBL16549273 | 0.78 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL21302008 | 0.75 | ALDH1A1 (0.32) | ALDH1A1PIK3CD | |
| SCHEMBL20835190 | 0.75 | PLA2G1B (0.42) | — | |
| SCHEMBL408513 | 0.75 | ALDH1A1 (0.39) | ALDH1A1PIK3CD | |
| SCHEMBL12725369 | 0.75 | SLC2A1 (0.36) | SLC2A1 | |
| SCHEMBL21283111 | 0.74 | MAOB (0.33) | — | |
| SCHEMBL22823681 | 0.73 | PLA2G1B (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2021-09-23 | — | — | US | disclosed |
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292323-A1 | Quinolone Derivatives as Fibroblast Growth Factor Inhibitors | FGFR1, FGFR3, FGFR2 | ALDH1A1 938/4885SLC2A1 3343/4885PIK3CD 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.